Vertex Pharmaceuticals (VRTX) is a publicly traded Healthcare sector company. As of August 19, 2026, VRTX trades at $530.46 with a market cap of $130.67B and a P/E ratio of 30.48. VRTX moved +2.47% today. Year to date, VRTX is +16.51%; over the trailing twelve months it is +35.48%. Its 52-week range spans $362.50 to $546.17. Analyst consensus is strong buy with an average price target of $565.32. Rallies surfaces VRTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks VRTX insider trades, Form 4 activity, executive purchases, executive sales, shares, prices, and transaction dates when available.
| Metric | Value |
|---|---|
| Price | $530.46 |
| Market Cap | $130.67B |
| P/E Ratio | 30.48 |
| EPS | $17.33 |
| Dividend Yield | 0.00% |
| 52-Week High | $546.17 |
| 52-Week Low | $362.50 |
| Volume | 1.13M |
| Avg Volume | 0 |
| Revenue (TTM) | $12.59B |
| Net Income | $4.41B |
| Gross Margin | 86.00% |
26 analysts cover VRTX: 0 strong buy, 21 buy, 4 hold, 1 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $565.32.